Dr. Parker is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3855 Health Sciences Dr
Mail Code 0987
La Jolla, CA 92093Phone+1 858-249-3248Fax+1 858-249-3250
Summary
- I am a breast medical oncologist and former senior cancer center administrator with over 30 years of experience in clinical care, clinical and translational research, cancer strategic planning and cancer clinical operations.
Education & Training
University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 1985 - 1987- University of California (San Diego) Medical CenterChief Residency, Internal Medicine, 1984 - 1985
- University of California (San Diego) Medical CenterResidency, Internal Medicine, 1981 - 1984
Stanford University School of MedicineClass of 1981
Certifications & Licensure
CA State Medical License 1982 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top Docs San Diego 2006-2020
- Lifetime Achievement Award American Cancer Society San Diego, 2019
- Lifetime Achievement Award UCSD Moores Cancer Center, 2018
- Join now to see all
Clinical Trials
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
- S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Publications & Presentations
PubMed
- 4 citationsA deep learning model of tumor cell architecture elucidates response and resistance to CDK4/6 inhibitors.Sungjoon Park, Erica Silva, Akshat Singhal, Marcus R Kelly, Kate Licon
Nature Cancer. 2024-07-01 - 2 citationsCorrection: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer.Rebecca A Shatsky, Hemali Batra-Sharma, Teresa Helsten, Richard B Schwab, Emily I Pittman
Breast Cancer Research. 2024-03-13 - 2 citationsA phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer.Rebecca A Shatsky, Hemali Batra-Sharma, Teresa Helsten, Richard B Schwab, Emily I Pittman
Breast Cancer Research. 2024-02-26
Press Mentions
Researchers to Test Novel Drug Combination Against Toughest Breast CancersAugust 27th, 2018
UCSD Launches New Clinical Trial for Breast Cancer DrugAugust 27th, 2018
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
